Related Experiment Video
Updated: Nov 5, 2025
05:19
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
Published on: March 29, 2019
10.6K
Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis
Amir Hossein Aalami1, Hossein Abdeahad2, Mohammad Mesgari3
1Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Biomed Research International
|May 17, 2021
Summary
Urinary angiogenin (ANG) shows potential as a biomarker for bladder cancer (BCa) detection. This meta-analysis confirms ANG
Area of Science:
- Urology
- Oncology
- Biomarker Discovery
Background:
- Bladder cancer (BCa) presents significant morbidity and mortality globally.
- Early detection of BCa is critical for improving patient prognosis.
- Reliable urinary biomarkers are needed for non-invasive BCa diagnosis.
Purpose of the Study:
- To evaluate the diagnostic accuracy of urinary angiogenin (ANG) protein for detecting bladder cancer.
- To perform a meta-analysis of existing studies on ANG as a urinary biomarker for BCa.
Main Methods:
- Systematic literature search across major scientific databases (PubMed, Scopus, Web of Science, etc.) up to October 2020.
- Meta-analysis of four case-control studies involving 656 participants (417 BCa cases, 239 controls).
- Statistical analysis using Meta-Disc and Comprehensive Meta-Analysis software to calculate pooled sensitivity, specificity, AUC, DOR, and likelihood ratios.
Main Results:
- The meta-analysis included four studies with 656 participants.
- Pooled diagnostic accuracy metrics: sensitivity 0.71, specificity 0.78, AUC 0.789, DOR 9.99.
- These results indicate acceptable diagnostic precision for ANG in identifying BCa.
Conclusions:
- Urinary angiogenin (ANG) demonstrates potential as a diagnostic biomarker for bladder cancer.
- ANG offers a fair diagnostic capability for BCa detection in urine samples.
- Further research may solidify ANG's role in clinical BCa screening.
